Why This MDMA Review Matters More Than It First Appears

an image of a worried man

I recently prepared a correspondence piece on a new narrative review about MDMA research. I may end up publishing my thoughts here instead, because one of the strange realities of academic publishing is that even a basic question like whether a short correspondence piece will incur page charges may go unanswered for days.

That, too, tells us something about how scientific authority is often maintained by appearances more than clarity.

Still, the paper itself is worth discussing.

The review by Ramaekers and colleagues is valuable because it does not present MDMA as an established therapy. Instead, it does something more careful and, in my view, more useful: it synthesizes what single-dose studies in healthy volunteers can actually tell us about MDMA’s subjective and neurocognitive effects, and it treats those findings as mechanistic hypotheses and safety-oriented guidance, not as proof of therapeutic efficacy [1].

That distinction matters.

A great deal of public discussion around MDMA, psilocybin, LSD, and other psychedelic-assisted interventions tends to jump too quickly from “interesting effects were observed” to “this is a treatment.” This review resists that jump. It reminds readers that even if MDMA increases trust, empathy, openness, or positive mood, those effects are not automatically equivalent to clinically meaningful benefit [1].

More importantly, the review does not focus only on desirable effects. It also highlights problems that are easy to underplay when enthusiasm runs high: vulnerability to boundary violations, subacute adverse experiences, interindividual variability, and methodological difficulty in trial design. The authors explicitly acknowledge that MDMA can compromise blinding and inflate expectancy, and that this may require active comparators and quantitative assessment of expectancy [1].

That point alone is important. It means this field cannot be reduced to a simple question of efficacy.

In ordinary drug development, the ideal model is relatively straightforward: a compound produces a measurable physiological effect, and that effect improves a clinical outcome. But psychedelic-assisted interventions are not so easy to isolate. Their effects may be shaped not only by pharmacology, but also by subjective experience, expectancy, the therapeutic relationship, and setting. In that sense, what is being evaluated is not simply a molecule, but a process [1,2].

This is one reason I think the review is especially useful. It organizes the field not as a list of exciting effects, but as a clinical and methodological problem. In areas such as trauma care, where subjective experience, therapeutic relationships, and ethical safeguards are deeply implicated in clinical judgment, this kind of narrative synthesis can help clarify what should be evaluated and what should be approached with particular caution [3].

That is also why I do not read this review as a simple endorsement of MDMA’s therapeutic promise. I read it as a starting point for a more careful conversation about what still needs to be examined.

If this field moves forward, it will not be enough to ask whether MDMA “works.” We will also need to ask how safety, ethics, individualization, and evaluation design should be positioned within the research itself. We will need to ask whether standard pharmacotherapy models are sufficient for interventions whose effects may be inseparable from context and relationship [1,2,3].

That does not mean evidence does not matter. It means the conditions under which evidence is produced may be unusually important here.

In that sense, the value of this review lies less in promoting MDMA as a therapy than in clarifying why this area of research should not be discussed in terms of efficacy alone [1].

References

1. Ramaekers JG, Kuypers KPC, Vollenweider FX. Subjective and neurocognitive profiling of clinical doses of 3,4-methylenedioxymethamphetamine (MDMA) in healthy volunteers: implications for therapeutic use. Molecular Psychiatry. Published online April 8, 2026. doi:10.1038/s41380–026–03602–7.
2. Szigeti B, Heifets BD. Expectancy effects in psychedelic trials. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging. 2024;9(5):512–521. doi:10.1016/j.bpsc.2024.02.004.
3. Reeves E. A synthesis of the literature on trauma-informed care. Issues in Mental Health Nursing. 2015;36(9):698–709. doi:10.3109/01612840.2015.1025319.